FC
SLDB icon

Finepoint Capital’s Solid Biosciences SLDB Stock Holding History

Finepoint Capital’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-961,251
Closed -$5.42M – 11
2025
Q4 		$5.42M Hold
961,251
– – 0.27% 5
2025
Q3 		$5.93M Hold
961,251
– – 0.34% 5
2025
Q2 		$4.68M Hold
961,251
– – 0.35% 5
2025
Q1 		$3.56M Hold
961,251
– – 0.27% 19
2024
Q4 		$3.85M Hold
961,251
– – 0.23% 20
2024
Q3 		$6.7M Hold
961,251
– – 0.49% 18
2024
Q2 		$5.45M Hold
961,251
– – 1.55% 16
2024
Q1 		$12.8M Hold
961,251
– – 3.28% 14
2023
Q4 		$5.9M Hold
961,251
– – 1.86% 17
2023
Q3 		$2.42M Hold
961,251
– – 1.21% 16
2023
Q2 		$5.04M Buy
961,251
+472,394
+97% +$2.66M 1.74% 20
2023
Q1 		$2.32M Buy
488,857
+270,295
+124% +$1.62M 0.89% 17
2022
Q4 		$1.18M Buy
+218,562
New +$1.43M 0.38% 20

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Finepoint Capital's SLDB Position: Q1 2026 in Review

Finepoint Capital sold out of Solid Biosciences (SLDB) in Q1 2026, closing a stake of 961,251 shares — an estimated $5.42M sold.

Finepoint Capital first reported a position in SLDB in Q4 2022 and held it in 13 quarters. The position peaked at $12.8M in Q1 2024. 150 funds tracked by Wall St. Rank hold SLDB as of Q1 2026.

  • Finepoint Capital reported no remaining Solid Biosciences position as of Q1 2026 after selling out during the quarter.
  • Finepoint Capital sold 961,251 Solid Biosciences shares in Q1 2026, an estimated $5.42M.
  • Finepoint Capital first reported a position in Solid Biosciences in Q4 2022 and held it in 13 quarters.
  • Finepoint Capital's Solid Biosciences position peaked at $12.8M in Q1 2024.
  • 150 funds tracked by Wall St. Rank held Solid Biosciences as of Q1 2026.

Based on Finepoint Capital's 13F filing for Q1 2026, filed 14 May 2026.